11 Most Shorted Stocks to Buy According to Analysts

6. Immunovant, Inc. (NASDAQ:IMVT)

Immunovant, Inc. (NASDAQ:IMVT) ranks among the most shorted stocks to buy according to analysts. On February 6, Immunovant, Inc. (NASDAQ:IMVT) released its Q3 2025 results, reporting a smaller-than-anticipated quarterly loss of -$0.61 per share, surpassing consensus projections of -$0.72 by $0.11.

The quarter’s net loss of $110.6 million was slightly higher than the $111.1 million for the same period a year earlier. Moreover, while general and administrative costs fell to $15.4 million from $19.8 million year-over-year, the company’s R&D expenditures rose to $98.9 million from $94.5 million.

Immunovant, Inc. (NASDAQ:IMVT) anticipates receiving topline findings in the latter half of 2026 from its proof-of-concept trial in cutaneous lupus erythematosus as well as its IMVT-1402 trial in rheumatoid arthritis. Furthermore, the company expects to release data from its Phase 3 trials of batoclimab for thyroid eye disease in the first half of this year.

Following the results, multiple analysts reiterated their views but raised price targets. Among them was Guggenheim analyst Yatin Suneja, who raised his target from $41 to $44 on February 9. In addition, Truist analyst Danielle Brill also reiterated a Hold rating on the stock but raised the target to $23 from $22.

Immunovant, Inc. (NASDAQ:IMVT) is a clinical-stage immunology company focused on developing innovative therapies for autoimmune diseases. The company’s primary focus is on creating anti-FcRn (neonatal Fc receptor) antibodies, which aim to reduce harmful immunoglobulin G (IgG) autoantibodies in patients with various autoimmune conditions.